PMC
Dược phẩm Dược liệu Pharmedic ·HNX ·2026Q1
▼ Under pressure
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, PMC is holding revenue at an acceptable level, but margins are eroding visibly — margins have been compressing consistently over multiple periods. What is still missing is better cost control to prevent margin pressure from spreading to the overall profit result.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 138.6 | 162.1 | 126.5 | 132.3 | 125.7 | 137.1 | 122.7 | 137.2 | 101.2 | 132.2 | 146.1 | 103.7 |
| Growth | -15% | +28% | -4% | +5% | -8% | +12% | -11% | +36% | -23% | -9% | +41% | — |
| Net Income | 22.9 | 17.9 | 19.4 | 22.4 | 22.7 | 19.8 | 21.5 | 24.2 | 14.7 | 24.7 | 20.8 | 22.9 |
| Net Margin | 16.54% | 11.02% | 15.32% | 16.91% | 18.06% | 14.42% | 17.51% | 17.63% | 14.52% | 18.68% | 14.21% | 22.13% |
Drivers of PMC's profit
Net profit attributable to parent declined vs last year, mainly due to higher selling expenses. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by higher gross profit. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE rose from 29.7% to 32.4% — mainly driven by leverage, despite net margin moving in the opposite direction.
Is the profit sustainable?
Margins narrowed but earnings quality remains clean — pressure is mainly operational.
What is driving the margin?
Net margin fell to 14.75%, losing 2.1pp. The main pressure is SG&A / Revenue rose 2.8pp, outweighing the improvement in Gross margin rose 1.6pp (in addition, Other profit / Revenue rose 0.0pp added support while Net financial result / Revenue fell 1.5pp remained a drag).
The pressure comes from non-core items while core operations hold their rhythm — margin has a basis to recover once this factor passes.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Capital efficiency should be read in industry context — ROIC may fluctuate with business specifics.
Is capital being deployed efficiently?
Track how much operating profit the business generates on invested capital.
Industry characteristics make ROIC cyclical — this is a reference signal and should be read with the business context.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC above should be read with industry context — the balance sheet below adds perspective. Capital structure is conservative with low leverage — liabilities at 0.43x equity, net debt at 0.06x equity.
Inventory ended the period at 103.9bn, roughly 30.1% of total assets.
Over the last 12 months, working capital absorbed 60.6bn of cash, mainly because of higher receivables and higher inventories. Part of that drag was offset by higher payables.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Cash conversion cycle lengthened by 18.8 days versus the same period last year. The main moves came from DIO rose 20.7 days, DSO rose 5.3 days, and DPO rose 7.2 days.
Working capital cycle lengthened mainly due to slower inventory turnover — more capital is being tied up in inventory.
Watchpoints
CCC stands at 112.2 days, suggesting that working capital remains tied up for a relatively long operating cycle.
DSO increased by +5.3 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Leverage is safe but FCF is negative at 97.3bn due to capex of 85.2bn — an investment choice, not an urgent risk.
Leverage & Liquidity
Track net leverage, interest coverage, and the liquidity buffer on the balance sheet.
At present, short-term debt accounts for 100.0% of total debt, cash equals 75.5% of debt, and total debt stands at 58.3bn.
Watchpoints
Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 20.7bn in 2025, against investing cash flow of 68.0bn.
Post-investment cash flow was positive +88.8bn. Financing cash flow was negative +108.3bn.
CFO / net income was -0.15x.
After spending +85.2bn on fixed-asset investment, the business generated trailing free cash flow of −97.3bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is under real pressure, but the current picture has not turned broadly adverse. A notable area has clearly weakened, making the near-term outlook hard to call bright; even so, other parts of the business are still holding up, with margins remain under pressure remaining the main constraint, with net margin down 2.1 pp. The next watchpoint is capital efficiency. The main offsetting support comes from earnings conversion is confirmed, with CFO/NI at -0.15x.
Improvement: earnings conversion looks more confirmed, with CFO / net income at -0.15x.
Watchpoint: Capital efficiency needs cycle context.
Key risk: profitability remains under pressure, with trailing-12M net margin at 14.75% after a 2.1pp decline versus the same period last year.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
|
Net Revenue
|
546.6 | 498.2 | 485.2 | 472.3 | 414.2 |
|
Cost of Goods Sold
|
323.4 | 311.0 | 315.1 | 285.9 | 0.0 |
|
Gross Profit
|
223.2 | 187.2 | 170.1 | 186.4 | 147.5 |
|
Financial Expenses
|
0.3 | 0.0 | 0.0 | 0.1 | -0.0 |
|
Selling Expenses
|
63.0 | 47.1 | 45.1 | 49.7 | -39.2 |
|
General and Administrative Expenses
|
62.3 | 49.6 | 40.6 | 45.9 | -35.7 |
|
Operating Profit
|
101.5 | 100.0 | 104.3 | 103.9 | 82.0 |
|
Profit Before Tax
|
103.0 | 100.3 | 104.6 | 104.5 | 81.3 |
|
Net Income
|
82.3 | 80.1 | 83.6 | 83.4 | 64.8 |
|
Profit Attributable to Parent
|
82.3 | 80.1 | 83.6 | 83.4 | 64.8 |
|
Earnings per Share
|
6,438.00 | 6,268.00 | 6,536.00 | 6,525.00 | 5,263.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.